Literature DB >> 23716550

No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis.

Valentina Poletto, Laura Villani, Paolo Catarsi, Rita Campanelli, Margherita Massa, Alessandro M Vannucchi, Vittorio Rosti, Giovanni Barosi.   

Abstract

Entities:  

Keywords:  XPD Lys751Gln; acute myeloid leukemia; leukemic transformation; primary meylofibrosis

Mesh：

Substances：

Year:  2013        PMID： 23716550      PMCID： PMC3729887          DOI： 10.3324/haematol.2013.086496

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  17 in total

1.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

2.  Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.

Authors:  N Gangat; A P Wolanskyj; R F McClure; C-Y Li; S Schwager; W Wu; A Tefferi
Journal:  Leukemia       Date:  2006-12-14       Impact factor: 11.528

Review 3.  Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

Authors:  Ruben A Mesa; Srdan Verstovsek; Francisco Cervantes; Giovanni Barosi; John T Reilly; Brigitte Dupriez; Ross Levine; Marie-Caroline Le Bousse-Kerdiles; Martha Wadleigh; Peter J Campbell; Richard T Silver; Alessandro M Vannucchi; H Joachim Deeg; Heinz Gisslinger; Deborah Thomas; Olatoyosi Odenike; Lawrence A Solberg; Jason Gotlib; Elizabeth Hexner; Stephen D Nimer; Hagop Kantarjian; Attilio Orazi; James W Vardiman; Juergen Thiele; Ayalew Tefferi
Journal:  Leuk Res       Date:  2007-01-08       Impact factor: 3.156

Review 4.  ERCC2/XPD gene polymorphisms and cancer risk.

Authors:  Simone Benhamou; Alain Sarasin
Journal:  Mutagenesis       Date:  2002-11       Impact factor: 3.000

5.  Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.

Authors:  Guido Finazzi; Vanesa Caruso; Roberto Marchioli; Giovanni Capnist; Teodoro Chisesi; Carlo Finelli; Luigi Gugliotta; Raffaele Landolfi; Jack Kutti; Heinz Gisslinger; Raphael Marilus; Carlo Patrono; Enrico Maria Pogliani; Maria Luigia Randi; Ana Villegas; Gianni Tognoni; Tiziano Barbui
Journal:  Blood       Date:  2004-12-07       Impact factor: 22.113

6.  Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.

Authors:  James M Allan; Alexandra G Smith; Keith Wheatley; Robert K Hills; Lois B Travis; Deirdre A Hill; David M Swirsky; Gareth J Morgan; Christopher P Wild
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113

7.  The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.

Authors:  Constantine S Tam; Roberto M Nussenzveig; Uday Popat; Carlos E Bueso-Ramos; Deborah A Thomas; Jorge A Cortes; Richard E Champlin; Stefan E Ciurea; Taghi Manshouri; Sherry M Pierce; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

8.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Authors:  Amy V Jones; Andrew Chase; Richard T Silver; David Oscier; Katerina Zoi; Y Lynn Wang; Holger Cario; Heike L Pahl; Andrew Collins; Andreas Reiter; Francis Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

9.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

10.  Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

Authors:  Francesco Passamonti; Elisa Rumi; Luca Arcaini; Emanuela Boveri; Chiara Elena; Daniela Pietra; Sabrina Boggi; Cesare Astori; Paolo Bernasconi; Marzia Varettoni; Ercole Brusamolino; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2008-09-11       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.